Please login to the form below
MedImmune
This page shows the latest MedImmune news and features for those working in and with pharma, biotech and healthcare.
Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition
Viela Bio spun out of AstraZeneca’s Medimmune biologics unit in 2018 with six molecules and $250m in funding from a number of investors.
Latest news
-
Medimmune-born Viela files $150m IPO, eyes first product launch
Funds will help to push a number of pipeline candidates. Almost two years after spinning out of AstraZeneca’s Medimmune biologics unit, Viela Bio has filed for an initial public offering
-
AZ says dropping MedImmune will help ‘streamline’ its R&D
Will also drop other candidates that haven’t hit the mark. The demise of the MedImmune brand, which has driven AstraZeneca’s biologics pipeline for more than a decade, will strengthen ... And in particular, whether its entrepreneurial culture could
-
AZ’s Sean Bohen to exit after business overhaul; report
Chief commercial officer Mark Mallon has taken on the CEO role at US biotech Ironwood Pharmaceuticals, while Medimmune research head Bahija Jallal agreed to take the helm of UK biotech company
-
AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
her post as research head of AZ’s biotech arm MedImmune to head up UK biotech company Immunocore. ... Mene Pangalos will be the leader of a new unified Research and Development unit for BioPharmaceuticals, ending the split between MedImmune biologics
-
Regeneron and Teva close gap on rivals with NGF pain drug
NGF inhibitors have had a chequered history, with a long list of discontinued candidates, mainly due to side effect issues, from the likes of AstraZeneca/Medimmune and AbbVie, amongst others.
More from news
Approximately 12 fully matching, plus 88 partially matching documents found.
Latest Intelligence
-
AstraZeneca’s oncology renaissance
Imfinzi, competing in the hypercompetitive world of immuno-oncology, was developed by MedImmune, the company’s US-based biologics research division, while the two small molecule drugs were developed in the ... The third area is immuno-oncology (IO)
-
AstraZeneca: building a new ‘open innovation’ pharma company
This physical environment gives us an opportunity to work in a different way,” said Jane Osbourn, the company’s site lead and vice-president for research and development at MedImmune, its
-
Deal Watch March 2017
Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up. ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development. MEDI8897; monoclonal antibody to respiratory syncytial virus in phase
-
Deal Watch October 2016
Licensee / Acquirer. Deal type. Product /technology. Headline $m. Medimmune / AstraZeneca (UK).
-
Deal Watch February 2016
We have seen this for several of the large pharma firms and this month AstraZeneca licensed an antibody developed by MedImmune to start-up company Corvidia Therapeutics concurrently with Corvidia's ... acquisition - corporate. 29.35. AstraZeneca/
More from intelligence
Approximately 1 fully matching, plus 13 partially matching documents found.
Latest appointments
-
New hires at Ferring, Flexion and Immunocore
Before Immunocore Berman most recently served as senior vice president and head of the AstraZeneca Immuno-oncology franchise, where he was responsible for early stage oncology programme MedImmune.
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Bahija has more than 25 years of international leadership experience within the pharmaceutical industry, and joins Immunocore from AstraZeneca, where she has served as President of MedImmune, its global biologics research ... Since joining MedImmune in
-
AZ and Medimmune bolsters immuno-oncology leadership
Dr Jean-Charles Soria and Dr Geoffrey Kim join the company. AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria, ... Soria also taking up a leadership role within AZ’s
-
AstraZeneca appoints head of oncology
Dr Jamie Freedman joins from AZ subsidiary MedImmune. AstraZeneca has appointed Dr Jamie Freedman as its new head of oncology, succeeding Dr Mondher Mahjoubi. ... Dr Freedman moves to AstraZeneca from its subsidiary MedImmune, where he was senior vice
-
Nanobiotix strengthens US leadership team
He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.
More from appointments
Approximately 5 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
emotive Account Management team boosted following recent pitch wins
Having completed her Masters in Biotechnology from one of France’s most prestigious universities, Cécile has previously worked in laboratory settings and clinical trials with Re:Cognition Health and MedImmune, part
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
-
Head of Copy
-
£ competitive
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- Why pharma must get smart in its approach to customer engagement
- AstraZeneca's Enhertu receives FDA grant for priority review
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
- Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19
- SMC approves Parkinson’s disease treatment Ongentys
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- Home or away: where next for pharmaceutical symposia?
- PM announces plans to lift England’s COVID-19 restrictions
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Why pharma must get smart in its approach to customer engagement
- AstraZeneca's Enhertu receives FDA grant for priority review
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- Assessing the value of interim analyses in clinical trials
- European biotech: a new generation of leaders emerges
- A rough guide to... advisory boards
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
- Cervical Cancer Prevention Month
- In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
- 6 critical success factors for flawless execution of a rapid first commercial launch
- Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
